1] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Scince, 2009, 324(5930):1029-1033.
[2] Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis[J]. Cell Res, 2009,19(7):802-815.
[3] Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype[J]. Br J Cancer, 2010,102(3):561-569.
[4] Liu L, Ning X, Sun L, et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer[J]. Cancer Sci, 2008,99(1):121-128.
[5] Cao X, Fang L, Gibbs S, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia[J]. Cancer Chemother Pharmacol, 2007,59(4):495-505.
[6] Li SJ, Guo W, Ren GX, et al. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography[J]. Br J Oral Maxillofac Surg, 2008,46(3):180-186.
[7] Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies[J]. Cancer Chemother Pharmacol, 2008,61(3):377-393.
[8] Chung FY, Huang MY, Yeh CS, et al. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients[J]. BMC Cancer, 2009,9:241.
[9] Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action [J]. diabetes, 2005, 54(11): 3095-3102.
[10] Lennon R, Welsh GI, Singh A, et al. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1 [J]. Diabetologia ,2009, 52(9):1944-1952.
[11] Brophy S, Sheehan KM, McNamara DA, et al. GLUT-1 expression and response to chemoradiotherapy in rectal cancer[J]. Int J Cancer, 2009,125(12):2778-2782.
[12] Cao X, Fang L, Gibbs S, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia[J]. Cancer Chemother Pharmacol, 2007,59(4):495-505.
[13] Airley RE, Phillips RM, Evans AE, et al. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts[J]. Int J Oncol, 2005,26(6):1477-1484.
[14] Smith TA, Sharma RI, Wang WG, et al. Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro[J]. Nucl Med Biol, 2007,34(8):955-960.
[15] Elbashir SM, Harborth J, Weber K, et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs[J]. Methods, 2002,26(2):199-213.
[16] Holen T, Amarzguioui M, Wiiger MT, et al. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor[J]. Nucleic Acids Res, 2002,30(8):1757-1766.
[17] Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region[J]. Nucleic Acids Res, 2004,32(2):691-699.
[18] Tian M, Zhang H, Nakasone Y, et al. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study[J]. Eur J Nucl Med Mol Imaging,2004 ,31(1):5-12.
[19] Bubnovskaya L, Mikhailenko V, Kovelskaya A, et al. Bioenergetic status and hypoxia in Lewis lung carcinoma assessed by 31P NMR spectroscopy: correlation with tumor progression[J]. Exp Oncol, 2007,29(3):207-211.
[20] Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study[J]. Cancer, 1993 ,72(10):2979-2985. |